{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:03:47Z","timestamp":1745294627151,"version":"3.40.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"DOI":"10.7759\/cureus.82716","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T17:11:51Z","timestamp":1745255511000},"source":"Crossref","is-referenced-by-count":0,"title":["A Stable Switch From Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/FTC\/TAF) to Dolutegravir\/Lamivudine (DTG\/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort"],"prefix":"10.7759","author":[{"given":"Jihad","family":"Slim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bellafiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masara","family":"Touza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2018.1442554","article-title":"Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment na\u00efve patients","volume":"30","author":"Hemmige V","year":"2018","unstructured":"Hemmige V, Flash CA, Carter J, Giordano TP, Zerai T. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment na\u00efve patients. AIDS Care. 2018, 30:1017-24. 10.1080\/09540121.2018.1442554","journal-title":"AIDS Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ981","article-title":"The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States","volume":"62","author":"Girouard MP","year":"2016","unstructured":"Girouard MP, Sax PE, Parker RA, et al.. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016, 62:784-91. 10.1093\/cid\/civ981","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1438","article-title":"1603. Efficacy, safety and tolerability of switching to dolutegravir\/lamivudine in virologically suppressed adults living with HIV on bictegravir\/emtricitabine\/tenofovir alafenamide -the DYAD study","volume":"10","author":"Rolle CP","year":"2023","unstructured":"Rolle CP, Castano J, Nguyen V, Hinestrosa F, DeJesus E. 1603. Efficacy, safety and tolerability of switching to dolutegravir\/lamivudine in virologically suppressed adults living with HIV on bictegravir\/emtricitabine\/tenofovir alafenamide -the DYAD study. Open Forum Infect Dis. 2023, 10:ofad500.1438. 10.1093\/ofid\/ofad500.1438","journal-title":"Open Forum Infect Dis"},{"key":"ref4","unstructured":"No confirmed virological failures (CVF) for 144 weeks when switching 2-\/3-\/4-drug ART to DTG\/3TC in heavily treatment-experienced PLWHA with prior M184V\/I and multiple virological failures in the prospective SOLAR-3D study. (2024). Accessed. October 12, 2024: https:\/\/www.natap.org\/2024\/IAS\/IAS_01.htm."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini R","year":"2018","unstructured":"Gagliardini R, Ciccullo A, Borghetti A, et al.. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018, 5:ofy113. 10.1093\/ofid\/ofy113","journal-title":"Open Forum Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12611","article-title":"Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. [Online ahead of print]","author":"Borghetti A","year":"2018","unstructured":"Borghetti A, Baldin G, Lombardi F, et al.. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. [Online ahead of print]. HIV Med. 2018, 10.1111\/hiv.12611","journal-title":"HIV Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002394","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials: erratum","volume":"84","year":"2020","unstructured":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection. 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials: erratum. J Acquir Immune Defic Syndr. 2020, 84:e21. 10.1097\/QAI.0000000000002394","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","unstructured":"Dovato. (2019). Accessed. October 12, 2024: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Dovato\/pdf\/DOVATO-PI-PIL.PDF."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S216067","article-title":"Dolutegravir and lamivudine combination for the treatment of HIV-1 infection","volume":"11","author":"Zamora FJ","year":"2019","unstructured":"Zamora FJ, Dowers E, Yasin F, Ogbuagu O. Dolutegravir and lamivudine combination for the treatment of HIV-1 infection. HIV AIDS (Auckl). 2019, 11:255-63. 10.2147\/HIV.S216067","journal-title":"HIV AIDS (Auckl)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab583","article-title":"Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014-2018","volume":"74","author":"McClung RP","year":"2022","unstructured":"McClung RP, Oster AM, Ocfemia MC, Saduvala N, Heneine W, Johnson JA, Hernandez AL. Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014-2018. Clin Infect Dis. 2022, 74:1055-62. 10.1093\/cid\/ciab583","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta RK","year":"2009","unstructured":"Gupta RK, Hill A, Sawyer AW, et al.. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009, 9:409-17. 10.1016\/S1473-3099(09)70136-7","journal-title":"Lancet Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Van Wyk J","year":"2020","unstructured":"Van Wyk J, Ajana F, Bisshop F, et al.. Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020, 71:1920-9. 10.1093\/cid\/ciz1243","journal-title":"Clin Infect Dis"},{"key":"ref13","unstructured":"Non-inferior efficacy and less weight gain when switching to DTG\/3TC than when switching to BIC\/FTC\/TAF in virologically suppressed people with HIV (PWH). the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. (2024). Accessed: October 12, 2024: https:\/\/www.natap.org\/2024\/IAS\/IAS_06.htm."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad526","article-title":"Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V\/I: a systematic literature review and meta-analysis","volume":"10","author":"Kabra M","year":"2023","unstructured":"Kabra M, Barber TJ, Allavena C, et al.. Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V\/I: a systematic literature review and meta-analysis. Open Forum Infect Dis. 2023, 10:ofad526. 10.1093\/ofid\/ofad526","journal-title":"Open Forum Infect Dis"},{"key":"ref15","unstructured":"Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate. real-world assessment of weight gain in na\u00efve people living with HIV of Asian origin (DRAGON study). (2024). Accessed: December 12, 2024: https:\/\/www.natap.org\/2024\/Glasgow\/GLASGOW_74.htm."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351099-a-stable-switch-from-bictegraviremtricitabinetenofovir-alafenamide-bftctaf-to-dolutegravirlamivudine-dtg3tc-in-the-absence-of-historical-resistance-records-results-from-the-switch-to-dovato-in-patients-suppressed-on-biktarvy-sound-cohort","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T17:11:53Z","timestamp":1745255513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351099-a-stable-switch-from-bictegraviremtricitabinetenofovir-alafenamide-bftctaf-to-dolutegravirlamivudine-dtg3tc-in-the-absence-of-historical-resistance-records-results-from-the-switch-to-dovato-in-patients-suppressed-on-biktarvy-sound-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.82716","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}